Having established CBD’s known anti-inflammatory properties and benefits in many of our previous blogs and posts, here are some pre and post clinical studies we have found that have been done on Chron’s disease and other inflammatory bowel diseases. Unfortunately, there is not much info out there yet, but if you understand CBD’s effects on inflammation and our endocannabinoid system, you should be excited about CBD’s possible benefits. Having known people with this disease, we can say it is terrible. We hope you find relief!
What is Chron’s
An inflammatory bowel disease (IBD) that causes inflammation of the digestive tract. Symptoms range from mild to life threating and usually include abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. The inflammation often spreads deep into the layers of affected bowel tissue and can be both painful and debilitating, and sometimes may lead to life-threatening complications.
Here are some articles we pulled off of NCBI that will give you more info on CBD’s possible benefits.
Over the last decade, interest in the therapeutic potential of cannabis and its constituents (e.g. cannabidiol) in the management of inflammatory bowel diseases (IBD) has escalated. Cannabis has been increasingly approved for a variety of medical conditions in several jurisdictions around the world. In animal models, cannabinoids have been shown to improve intestinal inflammation in experimental models of IBD through their interaction with the endocannabinoid system. However, the few randomized controlled trials of cannabis or cannabidiol in patients with IBD have not demonstrated efficacy in modulating inflammatory disease activity. Cannabis may be effective in the symptomatic management of IBD. Given the increasing utilization and cultural acceptance of cannabis, physicians need to be aware of its safety and efficacy in order to better counsel patients. The aim of this review is to provide an overview of the role of cannabis in the management of patients with IBD.”
Introduction: Cannabis use among inflammatory bowel disease (IBD) patients is common. There are many studies of various laboratory models demonstrating the anti-inflammatory effect of cannabis, but their translation to human disease is still lacking. Areas covered: The cannabis plant contains many cannabinoids, that activate the endocannabinoid system. The two most abundant phytocannabinoids are the psychoactive Tetrahydrocannabinol (THC), and the (mostly) anti-inflammatory cannabidiol (CBD). Approximately 15% of IBD patients use cannabis to ameliorate disease symptoms. Unfortunately, so far there are only three small placebo-controlled study regarding the use of cannabis in active Crohns disease, combining altogether 93 subjects. Two of the studies showed significant clinical improvement but no improvement in markers of inflammation. Expert opinion: Cannabis seems to have a therapeutic potential in IBD. This potential must not be neglected; however, cannabis research is still at a very early stage. The complexity of the plant and the diversity of different cannabis chemovars create an inherent difficulty in cannabis research. We need more studies investigating the effect of the various cannabis compounds. These effects can then be investigated in randomized placebo controlled clinical trials to fully explore the potential of cannabis treatment in IBD.”
Introduction: Fifty years after the discovery of Δ9-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential treatment is given. From first surveys and small clinical studies in patients with IBD we have learned that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are responsible for these effects. Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are already available with a narcotic prescription.”
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
The contents of this website are for informational purposes only and do not constitute medical advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Individual customer experiences with Bella Jane Organics products may vary with respect to both effectiveness, and potential adverse reactions. Results given in testimonials are from real customers who have used Bella Jane Organics products, but similar results are not guaranteed. Individual results may vary depending on skin type, sensitivity, age, and skincare history, as well as how the product is applied.
Before use, it is advisable to test the product on a small area of skin to check for sensitivity or allergic reaction. Should irritation occur, adjust usage accordingly. If irritation persists, discontinue use, and in the unlikely case of severe irritation seek professional medical advice. Bella Jane Organics accepts no responsibility or liability for any adverse consequences resulting directly or indirectly from the use of our products.
Contact your doctor immediately if you suspect that you have a medical problem or emergency.